Renal involvement in Anderson-Fabry disease

Journal of Nephrology

Volumn 16, Issue 2, 2003, Pages 310-313

  Sessa, Adalberto ^a   Meroni, Mietta ^a   Battini, Graziana ^a   Righetti, Marco ^a   Maglio, Alessia ^a   Tosoni, Antonella ^b   Nebuloni, Manuela ^b   Vago, Gianluca ^b   Giordano, Ferdinando ^a  

^a DESIO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Anderson Fabry disease; Electron microscopy; End stage renal failure; Enzyme replacement therapy; Hereditary nephritis; Lisosomal storage disorders

Indexed keywords

ALPHA GALACTOSIDASE; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; GLYCOSPHINGOLIPID;

BLEEDING; BLOOD VESSEL; CELL LINE; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CYTOPLASM; DEATH; DIALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; ENZYME REPLACEMENT; EPITHELIUM CELL; FABRY DISEASE; GENE THERAPY; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONDUCTION DISTURBANCE; HEMANGIOKERATOMA; HEMIZYGOSITY; HETEROZYGOSITY; HUMAN; KIDNEY BIOPSY; KIDNEY CELL; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY TRANSPLANTATION; NEUROLOGIC DISEASE; NONHUMAN; PARESTHESIA; PATHOPHYSIOLOGY; SKIN DEFECT; SURVIVAL RATE; THROMBOSIS; X CHROMOSOME LINKED DISORDER; ADULT; CASE REPORT; CHRONIC KIDNEY FAILURE; COMORBIDITY; FEMALE; GENETICS; INCIDENCE; MALE; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; SEX RATIO;

ADULT; BIOPSY, NEEDLE; COMORBIDITY; DISEASE PROGRESSION; FABRY DISEASE; FEMALE; GLYCOSPHINGOLIPIDS; HUMANS; INCIDENCE; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; MALE; PROGNOSIS; RISK FACTORS; SEX DISTRIBUTION;

EID: 0041519228     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease: Ceramide trihexosidase deficiency. N Engl J Med 1967; 276: 1163-7.
2. Eng CM, Resnick DJ, Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the α-galactosidase A activity gene that cause Fabry disease. Am J Hum Genet 1993; 53: 1186-97.
3. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A Deficiency. Fabry Disease. The Metabolic and Molecular Bases of Inherited Disease (7th ed). New York: Mc Graw Hill 1995; 2741-84.
4. Ashton-Prolla P, Tong B, Shabbeer J. Fabry disease: Twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Med Invest 2000; 48: 227-35.
5. Nakao S, Takenaka T, Maeda M, Kodama C. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333: 288-93.
6. Meroni M, Spisni C, Tazzari S, Sessa A. Isolated glomerular proteinuria as the only clinical manifestation of Fabry's disease in an adult male. Nephron Dial Transplant 1997; 12: 221-3.
7. Sessa A, Meroni M, Battini G, Amato M. "Atypical" clinical variants of Anderson-Fabry disease. Nephron 2001; 89: 469-70.
8. Lyon MF. Gene action in the X-chromosome of the mouse. (Mus musculus L.). Nature 1961; 190: 372-3.
9. Meroni M, Sessa A, Battini G, Tazzari S, Torri Tarelli L. Kidney involvement in Anderson-Fabry disease. Contrib Nephrol 1997; 122: 178-84.
10. Sessa A, Cianciaruso B, Pisani A, Andreucci MV. Anderson-Fabry Nephropathy with Superimposed IgA Glomerulonephritis. (personal data).
11. Faraggiana T, Churg J, Grishman E. Light- and electron-microscopic histochemistry of Fabry's disease. Am J Pathol 1981; 103: 247.
12. Sessa A, Tosoni A, Nebuloni M, Pallotti F, Giordano F, Battini G, Maglio A, Meroni M. Renal ultrastructural findings in Anderson-Fabry disease. J Nephrol 2002; 15: 109-12.
13. Khoshnoodi J, Tryggvason K. Congenital nephrotic syndrome. Curr Opin Genet Dev 2001; 11: 322-7.
14. Kang DH, Kamellis J, Hugo C, Truong L. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13: 806-16.
15. Farge D, Nadler S, Wolfe LS. Diagnostic value of kidney biopsy in heterozygous Fabry's disease. Arch Pathol Lab Med 1985; 109: 85-8.
16. Chen HC, Tsai JH, Lai YH, Guh JY. Renal changes in heterozygous Fabry's disease: A family study. Am J Kidney Dis 1990; 15: 180-3.
17. Sessa A, Meroni M, Battini G, Maglio A, Nebuloni M, Tosoni A, Panichi V, Bertagnolio B. Renal transplantation in patients with Fabry disease. Nephron 2002; 91: 348-51.
18. Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, Obrador GT. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002; 61: 249-55.
19. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750-60.
20. Kramer W, Thormann J, Mueller K, Frenzel H. Progressive cardiac involvement by Fabry's disease despite successful renal allotransplantation. Int J Cardiol 1985; 7: 72-5.
21. Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A, Kaplan B. Excellent outcome of renal transplantation in patients with Fabry's disease. Transplantation 2000; 69: 2337-9.
22. Mosnier JF, Degott C, Bedrossian J. Recurrence of Fabry's disease in a renal allograft eleven years after successful renal transplantation. Transplantation 1991; 51: 759-62.
23. Schiffmann R, Kopp JB, Austin H, Moore DF, Sabnis S, Weibel T, Balow JE, Brady RO. Efficacy and safety of enzyme replacement therapy for Fabry disease demonstrated by a double-blind placebo controlled trial. Fifth Annual Meeting of the American Society of Human Genetics. Philadelphia, Pennsylvania October 2000; 3-7.
24. Eng CM, Guffon N, Wilcox WR. Safety and efficacy of recombinant human α-galactosidase A replacement in Fabry's disease. N Engl J Med 2001; 345: 9-16.
25. Pastores GM, Thadhani R. Advances in the management of Anderson-Fabry disease: Enzyme replacement therapy. Expert Opin Biol Ther 2002; 2: 1-9.
26. Moore DF, Altarescu A, Ling GSF. Cerebrovascular hyperdynamicity in Fabry disease with reversal following enzyme replacement therapy. Stroke 2002 (in press).
27. Frustaci A, Chimenti C, Ricci R, Natale L. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose infusion therapy. N Engl J Med 2001; 345: 25-32.
28. Sakuraba H, Igarashi T, Shibata T, Suzuki Y. Effect of vitamin E and ticlopidine on platelet aggregation in Fabry's disease. Clin Genet 1987; 31: 349-54.
29. Schiffmann R, Kopp JB, Austin HA 3rd. Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 2001; 285: 2743-9.